drugset / Trial / NCT05687071
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
NaSingle-groupOpen-labelTreatment
Summary
A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg administered for 52 weeks in patients with hyper-LDL cholesterolemia
Timeline
- Start
- 2023-02-27
- Primary completion
- 2024-10-05
- Completion
- 2024-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempedoic acid | Small molecule | 180 mg | — |